FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2722-2723 December 28, 2006 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In March 2004, the Food and Drug Administration (FDA) issued a public health advisory regarding worsening depression and suicidal thoughts and behavior in patients treated with the newer antidepressant drugs fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox), citalopram (Celexa), escitalopram (Lexapro), bupropion (Wellbutrin), venlafaxine (Effexor), nefazodone (Serzone), and mirtazapine (Remeron). In February 2005, the agency extended the warning to include all antidepressant drugs. This warning was prompted by analyses of data from placebo-controlled trials of antidepressants suggesting that the drugs were associated with an increased risk of suicidal behavior in children and adolescents.

Subsequent research leaves considerable uncertainty regarding . . . [Full Text of this Article]

Source Information

Dr. Simon is an investigator in the Center for Health Studies at Group Health Cooperative, Seattle, and is the chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance, which is funded by pharmaceutical and medical device companies, as well as by private donations.

This article has been cited by other articles:

• Kurian, B. T., Ray, W. A., Arbogast, P. G., Fuchs, D. C., Dudley, J. A., Cooper, W. O. (2007). Effect of Regulatory Warnings on Antidepressant Prescribing for Children and Adolescents. Arch Pediatr Adolesc Med 161: 690-696 [Abstract] [Full Text]